Buy Benemid
Benemid

$0.76
Active Ingredient
Delivery
Airmail (14-21 days) | EMS trackable (5-9 days)
Prescription
Issued on site / Included
Availability
In Stock
Product is shipped in a fully discreet envelope with no content disclosure, including all required documentation inside

Benemid Properties

Active Ingredients
Pharmacological Class
Uricosuric
Minor Side Effects
Moderate Side Effects
Dosage Forms
Tablets
Administration Route
Oral
Mechanism of Action
Helps the kidneys remove uric acid from the body, which lowers uric acid levels in the blood.
Prescription Status
Rx
Manufacturer
Valeant Pharmaceuticals
Patient Summary
A medication used to help manage gout by lowering uric acid levels and sometimes used with antibiotics to boost their effectiveness.
Onset Time
May take several months to see full effect on uric acid levels
Duration
Varies based on dosage and frequency
Storage Instructions
Store at room temperature
Age Restrictions
Not for use in children under 2
Pregnancy Use
Consult doctor before use during pregnancy or breastfeeding
Alternative Drugs

About Benemid

Benemid (generic name probenecid) is a uricosuric medication prescribed primarily to lower serum uric acid levels in adults with gout or chronic hyperuricemia. It belongs to the class of renal tubular transport inhibitors and is taken as an oral tablet, most commonly in a 500 mg strength. In Singapore, Benemid is available only with a prescription and is used in a range of kidney-related and metabolic conditions where excess uric acid contributes to disease progression.

What is Benemid?

Benemid is the brand name under which probenecid is marketed in many countries, including Singapore. The drug was first introduced in the -s as one of the earliest agents that promoted urinary excretion of uric acid. While the original manufacturer of the brand is not widely disclosed in Singapore’s public drug registries, the active ingredient is identical to the generic probenecid sold worldwide. Because the tablet formulation is identical to the generic version, the therapeutic effect and safety profile are considered bio-equivalent, offering patients a reliable option when the brand is preferred or when insurance formularies list it specifically.

Regulatory agencies such as the Health Sciences Authority (HSA) classify Benemid as a prescription-only medicine (POM). Its primary therapeutic aim is to reduce serum urate concentrations, thereby preventing gout flares and protecting the kidneys from urate-induced injury. In addition to its uricosuric action, probenecid is known to interfere with renal tubular secretion of several organic anions, a property that has been exploited to increase plasma levels of certain antibiotics, notably penicillins. This secondary effect is reflected in clinical guidelines that sometimes recommend co-administration of probenecid with β-lactam antibiotics to prolong their antibacterial activity.

How Benemid Works

Probenecid acts on the proximal renal tubule, where it blocks the urate-transport protein URAT1 (SLC22A12). Under normal physiology, URAT1 re-absorbs uric acid from the tubular lumen back into the bloodstream. By inhibiting this transporter, Benemid reduces the amount of uric acid that is reclaimed, increasing its clearance in the urine. The net result is a fall in serum urate levels that can be as much as 30-40 % in responsive individuals.

Pharmacokinetically, Benemid is well absorbed after oral administration, reaching peak plasma concentrations within 1 to 2 hours. It undergoes limited hepatic metabolism and is excreted largely unchanged in the urine. The drug’s half-life ranges from 4 to 7 hours, which supports once- or twice-daily dosing depending on the therapeutic goal and the patient’s renal function. Because the medication is eliminated by the kidneys, patients with severe renal impairment may experience reduced drug clearance, necessitating careful dose adjustment or alternative therapy.

The uricosuric effect explains why Benemid is effective in gout: lower circulating urate reduces crystal formation in joints and soft tissues, diminishing the inflammatory cascade that triggers painful attacks. In chronic kidney disease, sustained hyperuricemia can accelerate nephron loss through oxidative stress and endothelial dysfunction; by keeping urate levels in a target range, Benemid may help slow this progression, although the evidence remains under active investigation.

Why Benemid Is Used for Kidney Conditions and Metabolic Disorders

  • Gout prophylaxis - Elevated serum urate is the central pathogenic factor in gout. By enhancing uric acid excretion, Benemid maintains urate concentrations below the solubility threshold, preventing monosodium urate crystals from depositing in joints. Clinical guidelines recommend urate-lowering therapy for patients who experience recurrent attacks or who have tophaceous deposits, and Benemid remains an alternative when xanthine oxidase inhibitors are contraindicated or insufficient.

  • Chronic hyperuricemia without gout - Some patients present with persistently high urate levels that are not yet symptomatic but pose a risk for kidney stone formation and vascular disease. Probenecid’s ability to lower urate makes it a reasonable option for long-term control, especially when lifestyle measures alone fail to achieve target levels.

  • Urate-related kidney stones - Uric acid stones develop in acidic urine when urate concentration exceeds solubility. By reducing the filtered load of uric acid, Benemid decreases the likelihood of stone nucleation. Physicians often pair the drug with urine alkalinisation to optimise stone prevention.

  • Adjunct to β-lactam antibiotics - Probenecid inhibits renal tubular secretion of penicillins, thereby raising and prolonging their serum concentrations. In infections where high antibiotic exposure is critical-such as syphilis or meningitis-clinicians may prescribe a single dose of Benemid alongside the antibiotic to enhance efficacy while using lower antibiotic doses.

  • Metabolic syndrome management - Emerging data suggest a relationship between hyperuricemia and insulin resistance. Some investigators have observed modest improvements in fasting glucose and blood pressure when urate is lowered, although these findings are not yet incorporated into routine practice guidelines. Probenecid’s urate-lowering action provides a mechanistic rationale for its occasional use in metabolic research settings.

Off-Label and Investigational Uses of Benemid

Beyond its approved indications, Benemid has been explored in a few off-label contexts. Small observational studies have reported that urate-lowering therapy, including probenecid, may attenuate the progression of early chronic kidney disease when combined with renin-angiotensin system blockers. The proposed mechanism is reduction of urate-induced oxidative stress within renal tubules. Off-label use only under qualified healthcare provider supervision.

Another niche application involves the management of certain types of drug-

External Resources about Benemid


Information Prepared By

Nawin Kittisak
Vikneswaran V Paranjothy